The WRN gene was recognized as a tumor-suppressor gene and evidence suggests that it plays a role in promoting oncogenic proliferation [39, 40] which may likely contribute to AML transformation in Patient 5, in addition to the NPM1 and IDH2 mutations. This evidence concerns the gene NPM1 and acute myeloid leukemia.